Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 398.4 g/mol |
---|---|
Molecular Formula | C18H14N4O5S |
XLogP3 | 2.3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 6 |
Exact Mass | 398.06849073 g/mol |
Monoisotopic Mass | 398.06849073 g/mol |
Topological Polar Surface Area | 146 A^2 |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 804 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 6 | |
---|---|
Drug Name | Azulfidine |
PubMed Health | Salicylate (Oral route, Rectal route) |
Drug Classes | Antirheumatic, Gastrointestinal Agent |
Drug Label | AZULFIDINE EN-tabs Tablets contain sulfasalazine, formulated in a delayed release tablet (enteric-coated), 500 mg, for oral administration.AZULFIDINE EN-tabs Tablets are film coated with cellulose acetate phthalate to retard disintegration of the tab... |
Active Ingredient | Sulfasalazine |
Dosage Form | Tablet; Suspension |
Route | Oral |
Strength | 500mg; 250mg/5ml |
Market Status | Prescription |
Company | Pharmacia And Upjohn |
2 of 6 | |
---|---|
Drug Name | Azulfidine en-tabs |
PubMed Health | Sulfasalazine (By mouth) |
Drug Label | AZULFIDINE EN-tabs Tablets contain sulfasalazine, formulated in a delayed release tablet (enteric-coated), 500 mg, for oral administration.AZULFIDINE EN-tabs Tablets are film coated with cellulose acetate phthalate to retard disintegration of the tab... |
Active Ingredient | Sulfasalazine |
Dosage Form | Tablet; Tablet, delayed release |
Route | oral; Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Pharmacia Upjohn; Pharmacia And Upjohn |
3 of 6 | |
---|---|
Drug Name | Sulfasalazine |
Drug Label | Sulfasalazine Tablets USP, 500 mg for Oral AdministrationTherapeutic classification: Anti-inflammatory agent.Chemical designation: 5-[[p-(2-Pyridylsulfamoyl)phenyl]azo]salicylic acid.Chemical Structure:The molecular weight of sulfasalazine is 398.39.... |
Active Ingredient | Sulfasalazine |
Dosage Form | Tablet; Tablet, delayed release |
Route | Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Vintage Pharms; Watson Labs |
4 of 6 | |
---|---|
Drug Name | Azulfidine |
PubMed Health | Salicylate (Oral route, Rectal route) |
Drug Classes | Antirheumatic, Gastrointestinal Agent |
Drug Label | AZULFIDINE EN-tabs Tablets contain sulfasalazine, formulated in a delayed release tablet (enteric-coated), 500 mg, for oral administration.AZULFIDINE EN-tabs Tablets are film coated with cellulose acetate phthalate to retard disintegration of the tab... |
Active Ingredient | Sulfasalazine |
Dosage Form | Tablet; Suspension |
Route | Oral |
Strength | 500mg; 250mg/5ml |
Market Status | Prescription |
Company | Pharmacia And Upjohn |
5 of 6 | |
---|---|
Drug Name | Azulfidine en-tabs |
PubMed Health | Sulfasalazine (By mouth) |
Drug Label | AZULFIDINE EN-tabs Tablets contain sulfasalazine, formulated in a delayed release tablet (enteric-coated), 500 mg, for oral administration.AZULFIDINE EN-tabs Tablets are film coated with cellulose acetate phthalate to retard disintegration of the tab... |
Active Ingredient | Sulfasalazine |
Dosage Form | Tablet; Tablet, delayed release |
Route | oral; Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Pharmacia Upjohn; Pharmacia And Upjohn |
6 of 6 | |
---|---|
Drug Name | Sulfasalazine |
Drug Label | Sulfasalazine Tablets USP, 500 mg for Oral AdministrationTherapeutic classification: Anti-inflammatory agent.Chemical designation: 5-[[p-(2-Pyridylsulfamoyl)phenyl]azo]salicylic acid.Chemical Structure:The molecular weight of sulfasalazine is 398.39.... |
Active Ingredient | Sulfasalazine |
Dosage Form | Tablet; Tablet, delayed release |
Route | Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Vintage Pharms; Watson Labs |
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
81
PharmaCompass offers a list of Sulfasalazine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sulfasalazine manufacturer or Sulfasalazine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sulfasalazine manufacturer or Sulfasalazine supplier.
PharmaCompass also assists you with knowing the Sulfasalazine API Price utilized in the formulation of products. Sulfasalazine API Price is not always fixed or binding as the Sulfasalazine Price is obtained through a variety of data sources. The Sulfasalazine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Azulfidine EN-tabs manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Azulfidine EN-tabs, including repackagers and relabelers. The FDA regulates Azulfidine EN-tabs manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Azulfidine EN-tabs API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Azulfidine EN-tabs manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Azulfidine EN-tabs supplier is an individual or a company that provides Azulfidine EN-tabs active pharmaceutical ingredient (API) or Azulfidine EN-tabs finished formulations upon request. The Azulfidine EN-tabs suppliers may include Azulfidine EN-tabs API manufacturers, exporters, distributors and traders.
click here to find a list of Azulfidine EN-tabs suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Azulfidine EN-tabs DMF (Drug Master File) is a document detailing the whole manufacturing process of Azulfidine EN-tabs active pharmaceutical ingredient (API) in detail. Different forms of Azulfidine EN-tabs DMFs exist exist since differing nations have different regulations, such as Azulfidine EN-tabs USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Azulfidine EN-tabs DMF submitted to regulatory agencies in the US is known as a USDMF. Azulfidine EN-tabs USDMF includes data on Azulfidine EN-tabs's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Azulfidine EN-tabs USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Azulfidine EN-tabs suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Azulfidine EN-tabs Drug Master File in Japan (Azulfidine EN-tabs JDMF) empowers Azulfidine EN-tabs API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Azulfidine EN-tabs JDMF during the approval evaluation for pharmaceutical products. At the time of Azulfidine EN-tabs JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Azulfidine EN-tabs suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Azulfidine EN-tabs Drug Master File in Korea (Azulfidine EN-tabs KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Azulfidine EN-tabs. The MFDS reviews the Azulfidine EN-tabs KDMF as part of the drug registration process and uses the information provided in the Azulfidine EN-tabs KDMF to evaluate the safety and efficacy of the drug.
After submitting a Azulfidine EN-tabs KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Azulfidine EN-tabs API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Azulfidine EN-tabs suppliers with KDMF on PharmaCompass.
A Azulfidine EN-tabs CEP of the European Pharmacopoeia monograph is often referred to as a Azulfidine EN-tabs Certificate of Suitability (COS). The purpose of a Azulfidine EN-tabs CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Azulfidine EN-tabs EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Azulfidine EN-tabs to their clients by showing that a Azulfidine EN-tabs CEP has been issued for it. The manufacturer submits a Azulfidine EN-tabs CEP (COS) as part of the market authorization procedure, and it takes on the role of a Azulfidine EN-tabs CEP holder for the record. Additionally, the data presented in the Azulfidine EN-tabs CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Azulfidine EN-tabs DMF.
A Azulfidine EN-tabs CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Azulfidine EN-tabs CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Azulfidine EN-tabs suppliers with CEP (COS) on PharmaCompass.
A Azulfidine EN-tabs written confirmation (Azulfidine EN-tabs WC) is an official document issued by a regulatory agency to a Azulfidine EN-tabs manufacturer, verifying that the manufacturing facility of a Azulfidine EN-tabs active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Azulfidine EN-tabs APIs or Azulfidine EN-tabs finished pharmaceutical products to another nation, regulatory agencies frequently require a Azulfidine EN-tabs WC (written confirmation) as part of the regulatory process.
click here to find a list of Azulfidine EN-tabs suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Azulfidine EN-tabs as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Azulfidine EN-tabs API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Azulfidine EN-tabs as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Azulfidine EN-tabs and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Azulfidine EN-tabs NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Azulfidine EN-tabs suppliers with NDC on PharmaCompass.
Azulfidine EN-tabs Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Azulfidine EN-tabs GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Azulfidine EN-tabs GMP manufacturer or Azulfidine EN-tabs GMP API supplier for your needs.
A Azulfidine EN-tabs CoA (Certificate of Analysis) is a formal document that attests to Azulfidine EN-tabs's compliance with Azulfidine EN-tabs specifications and serves as a tool for batch-level quality control.
Azulfidine EN-tabs CoA mostly includes findings from lab analyses of a specific batch. For each Azulfidine EN-tabs CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Azulfidine EN-tabs may be tested according to a variety of international standards, such as European Pharmacopoeia (Azulfidine EN-tabs EP), Azulfidine EN-tabs JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Azulfidine EN-tabs USP).